Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097409670> ?p ?o ?g. }
- W2097409670 endingPage "465" @default.
- W2097409670 startingPage "453" @default.
- W2097409670 abstract "More than 50 % of patients with colorectal cancer develop liver metastases. Surgical resection is the only available treatment that improves survival in patients with colorectal liver metastases (CRLM). New antiangiogenic targeted therapies, such as bevacizumab, aflibercept, and regorafenib, in combination with neoadjuvant and conversion chemotherapy may lead to improved response rates in this population of patients and increase the proportion of patients eligible for surgical resection. The present review discusses the available data for antiangiogenic targeted agents in this setting. One of these therapies, bevacizumab, which targets the vascular endothelial growth factor (VEGF) has demonstrated good results in this setting. In patients with initially unresectable CRLM, the combination of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab has led to high response and resection rates. This combination is also effective for patients with unresectable CRLM. Moreover, the addition of bevacizumab to chemotherapy in the neoadjuvant setting of liver metastasis has a higher impact on pathological response rate. This drug also has a manageable safety profile, and according to recent data, bevacizumab may protect against the sinusoidal dilation provoked in the liver by certain cytotoxic agents. In phase II trials, antiangiogenic therapy has demonstrated benefits in the presurgical treatment of CRLM and may represent a new treatment pathway for these patients." @default.
- W2097409670 created "2016-06-24" @default.
- W2097409670 creator A5017487956 @default.
- W2097409670 creator A5019511410 @default.
- W2097409670 creator A5034113777 @default.
- W2097409670 creator A5045523877 @default.
- W2097409670 creator A5045940617 @default.
- W2097409670 creator A5058227357 @default.
- W2097409670 creator A5059107350 @default.
- W2097409670 creator A5063929436 @default.
- W2097409670 creator A5079289582 @default.
- W2097409670 creator A5086357252 @default.
- W2097409670 creator A5090464803 @default.
- W2097409670 date "2015-03-11" @default.
- W2097409670 modified "2023-10-14" @default.
- W2097409670 title "Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents" @default.
- W2097409670 cites W122369139 @default.
- W2097409670 cites W1586129343 @default.
- W2097409670 cites W181486121 @default.
- W2097409670 cites W1891901463 @default.
- W2097409670 cites W1969328947 @default.
- W2097409670 cites W1973923565 @default.
- W2097409670 cites W1974494579 @default.
- W2097409670 cites W1974913186 @default.
- W2097409670 cites W1975798481 @default.
- W2097409670 cites W1980671105 @default.
- W2097409670 cites W1980725734 @default.
- W2097409670 cites W1984919087 @default.
- W2097409670 cites W1987403189 @default.
- W2097409670 cites W1989175303 @default.
- W2097409670 cites W1995881314 @default.
- W2097409670 cites W1996801596 @default.
- W2097409670 cites W1998005755 @default.
- W2097409670 cites W2007900522 @default.
- W2097409670 cites W2010129875 @default.
- W2097409670 cites W2015155974 @default.
- W2097409670 cites W2016912036 @default.
- W2097409670 cites W2019607817 @default.
- W2097409670 cites W2020830322 @default.
- W2097409670 cites W2021948632 @default.
- W2097409670 cites W2022950801 @default.
- W2097409670 cites W2029199150 @default.
- W2097409670 cites W2033734921 @default.
- W2097409670 cites W2034815616 @default.
- W2097409670 cites W2037108267 @default.
- W2097409670 cites W2039444733 @default.
- W2097409670 cites W2044576898 @default.
- W2097409670 cites W2057965634 @default.
- W2097409670 cites W2060959132 @default.
- W2097409670 cites W2062406653 @default.
- W2097409670 cites W2063356071 @default.
- W2097409670 cites W2066040529 @default.
- W2097409670 cites W2066390717 @default.
- W2097409670 cites W2067817921 @default.
- W2097409670 cites W2078345568 @default.
- W2097409670 cites W2081395858 @default.
- W2097409670 cites W2081772067 @default.
- W2097409670 cites W2084470612 @default.
- W2097409670 cites W2091723114 @default.
- W2097409670 cites W2094002672 @default.
- W2097409670 cites W2096910745 @default.
- W2097409670 cites W2096998881 @default.
- W2097409670 cites W2098370829 @default.
- W2097409670 cites W2110915643 @default.
- W2097409670 cites W2115735904 @default.
- W2097409670 cites W2124160356 @default.
- W2097409670 cites W2125877119 @default.
- W2097409670 cites W2129429593 @default.
- W2097409670 cites W2131515450 @default.
- W2097409670 cites W2131745440 @default.
- W2097409670 cites W2140085392 @default.
- W2097409670 cites W2142183513 @default.
- W2097409670 cites W2143743735 @default.
- W2097409670 cites W2144326782 @default.
- W2097409670 cites W2144425748 @default.
- W2097409670 cites W2145564580 @default.
- W2097409670 cites W2147834058 @default.
- W2097409670 cites W2149611344 @default.
- W2097409670 cites W2150286564 @default.
- W2097409670 cites W2151062573 @default.
- W2097409670 cites W2153003431 @default.
- W2097409670 cites W2154143304 @default.
- W2097409670 cites W2154414933 @default.
- W2097409670 cites W2155219235 @default.
- W2097409670 cites W2155263737 @default.
- W2097409670 cites W2155986971 @default.
- W2097409670 cites W2157769714 @default.
- W2097409670 cites W2158918006 @default.
- W2097409670 cites W2159179344 @default.
- W2097409670 cites W2165167463 @default.
- W2097409670 cites W2165741055 @default.
- W2097409670 cites W2165760078 @default.
- W2097409670 cites W2166573361 @default.
- W2097409670 cites W2171576276 @default.
- W2097409670 cites W2317687632 @default.
- W2097409670 cites W2334041313 @default.
- W2097409670 cites W2338874213 @default.
- W2097409670 cites W2340893063 @default.